National addictions vigilance intervention and prevention program (NAVIPPRO™): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse
National addictions vigilance intervention and prevention program (NAVIPPRO™): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse
复制标题
DOI：
10.1002/pds.1659
复制
发表时间：
2008-12-01
影响因子：
2.6
通讯作者：
Katz, Nathaniel
中科院分区：
文献类型：
--
作者：
Butler, Stephen F.;Budman, Simon H.;Katz, Nathaniel
目的国家成瘾警戒干预和预防计划(NAVIPPRO(TM))是一项针对定期治疗的科学、全面的风险管理计划。NAVIPPRO(TM)提供上市后监控、信号检测、信号验证以及预防和干预计划。在这里，我们关注NAVIPPRO(TM)监测的一个组成部分，成瘾严重指数-多媒体版本(注册商标)(ASI-MV(R))连接，这是一个连续、实时的全国性数据流，通过收集特定产品、地理详细信息来评估进入药物滥用治疗的患者的药物滥用情况。方法我们评估通过ASI-MV(注册商标)连接在2007年和2008年收集的数据的人口特征，并评估数据的代表性、地理覆盖率和报告的及时性。结果ASI-MV(R)Connect数据显示，11.5%的患者报告在进入药物滥用治疗前的30天内至少滥用一种阿片类止痛药；不同的处方阿片类药物滥用人群、不同产品和不同地理位置的患者之间存在差异。结论NAVIPPRO(TM)的ASI-MV(R)Connect成分为处方药上市后监测提供了潜在的有价值的数据流。利用从ASI-MV(R)Connect获得的数据进行的分析可以描述药物滥用的特定产品和地理空间差异，并可作为监测滥用人口对新开发的“滥用威慑”药物配方的反应的工具。更多的数据、评估和与其他系统的比较是将NAVIPPRO(TM)建立为综合系统的下一步重要步骤。处方药上市后监测系统。版权所有(C)2008 John Wiley&Sons，Ltd.
Purpose The National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO (TM)) is a scientific, comprehensive risk management program for scheduled therapeutics. NAVIPPRO (TM) provides post-marketing surveillance, signal detection, signal verification and prevention and intervention programs. Here we focus on one component of NAVIPPRO (TM) surveillance, the Addiction Severity Index-Multi media Version (R) (ASI-MV (R)) Connect, a continuous, real-time, national data stream that assesses pharmaceutical abuse by patients entering substance abuse treatment by collecting product-specific, geographically-detailed information.Methods We evaluate population characteristics for data collected through the ASI-MV (R) Connect in 2007 and 2008 and assess the representativeness, geographic coverage, and timeliness of report of the data. Analyses based on 41923 admissions to 265 treatment centers in 29 states were conducted on product-specific opioid abuse rates, source of drug, and route of administration.Results ASI-MV (R) Connect data revealed that 11.5% of patients reported abuse of at least one opioid analgesic product in the 30 days prior to entering substance abuse treatment; differences were observed among sub-populations of prescription opioid abusers, among products, and also within various geographic locations.Conclusions The ASI-MV (R) Connect component of NAVIPPRO (TM) represents a potentially valuable data stream for post-marketing surveillance of prescription drugs. Analyses conducted with data obtained from the ASI-MV (R) Connect allow for the characterization of product-specific and geospatial differences for drug abuse and can serve as a tool to monitor responses of the abuse population to newly developed "abuse deterrent" drug formulations. Additional data, evaluation, and comparison to other systems are important next steps in establishing NAVIPPRO (TM) as a comprehensive. post-marketing surveillance system for prescription drugs. Copyright (C) 2008 John Wiley & Sons, Ltd.